Existing therapies for CKD, e.g. RAS-blockade42 and sodium-glucose cotransporter 2 inhibition22, likely confer renoprotection through actions at both the cell and organ level and it seems reasonable to presume that the effects of EP4 inhibition are similarly broad. Here, SLC5A2 is linked to chronic kidney disease.